Summit Therapeutics Inc. — Q3 2020 Form 10-Q
Business context and reporting period. The filing reports the three and nine months ended September 30, 2020. Summit is a clinical-stage biopharmaceutical company focused on novel antibiotics, with ridinilazole in Phase 3 trials for Clostridioides difficile infection (CDI) and early-stage antibiotic research using its Discuva Platform. On September 18, 2020, the company completed a UK-to-Delaware redomiciliation; prior-period share amounts are presented on a retroactively adjusted basis.
Financial performance and position
- Revenue: Q3 revenue was $0.18 million, versus $0.15 million in Q3 2019. Nine-month revenue was $0.68 million, versus $0.80 million. Revenue primarily reflects the Eurofarma license agreement.
- Losses and expenses: Q3 net loss was $17.7 million ($0.26 per share), compared with $6.4 million ($0.20 per share). Nine-month net loss was $39.3 million ($0.58 per share), versus $20.0 million ($0.63 per share). Nine-month operating loss widened to $39.6 million from $19.8 million.
- Operating costs and support: Nine-month R&D expense rose 26% to $41.0 million, principally reflecting Phase 3 ridinilazole activity. G&A increased 70% to $13.4 million, including redomiciliation-related legal and professional fees. Other operating income declined 25% to $14.9 million, including $7.7 million from BARDA and $6.9 million in UK R&D tax credits.
- Cash flow: Nine-month cash used in operations was $40.1 million, compared with $13.9 million in 2019. Investing used $0.4 million; financing provided $0.003 million. Cash declined by $40.5 million, including the effect of foreign exchange.
- Liquidity and balance sheet: At September 30, cash and cash equivalents were $21.3 million, versus $63.8 million at year-end 2019. Current assets were $42.1 million and current liabilities $14.7 million. Total liabilities were $20.0 million; the balance sheet lists no borrowings. Accumulated deficit was $199.2 million. The filing does not provide a meaningful profit margin given minimal licensing revenue and ongoing development-stage losses.
Material changes and unusual items
- Q3 R&D expense increased 45% year over year; nine-month R&D rose 26%, primarily due to ridinilazole Phase 3 trials and related manufacturing activity.
- Nine-month G&A rose by $5.5 million, including $3.6 million of redomiciliation-related legal and professional fees. Q3 also included $1.8 million of unfavorable foreign-exchange movement in G&A.
- The company recorded a $0.9 million impairment of an option over non-financial assets in Q3, writing it off in full.
- Following the reporting period, on November 5, 2020, Summit raised $50 million gross through a private placement of 14,970,060 shares at $3.34 per share. Management expected existing cash, this financing and anticipated funding receipts to extend the cash runway into Q4 2021.
Outlook, risks and contingencies
- Summit expects continuing operating losses and states that it will need additional capital to complete its ridinilazole Phase 3 program. The filing warns that, without further funding, mitigating actions would fund operations and capital needs for only a short period beyond 12 months from issuance; this represents a material uncertainty that may raise significant doubt about the company’s ability to continue as a going concern.
- Management expects to use available funds for the ridinilazole Phase 3 program, potential-launch preparations, early-stage research and general corporate purposes. Additional financing may involve equity dilution, debt restrictions, or granting rights through collaborations or licenses.
- BARDA had committed $62.4 million of funding as of September 30, 2020; $47.0 million had been received. Further funding depends in part on BARDA exercising its remaining option and specified milestones.
- COVID-19 had disrupted some trial-site operations and enrollment, with potential for delayed results, increased development costs, and clinical-supply replacement. Further effects on trials, suppliers, personnel and financing remain uncertain.
- Eurofarma milestone and product-supply payments depend on enrollment, regulatory, commercial and sales achievements. No material legal proceedings were reported; management reported disclosure controls effective at a reasonable level of assurance.
Key facts for investors to verify
- Whether the November 2020 financing and expected BARDA and R&D tax-credit receipts support the stated runway into Q4 2021, and when further financing may be needed.
- Current enrollment, timing and outcomes of both ridinilazole Phase 3 trials, including the continuing effects of COVID-19.
- BARDA’s remaining funding options, milestones and reimbursement timing, alongside the timing of Eurofarma milestones.
- Drivers of rising R&D and G&A costs, and whether spending or trial timelines differ materially from management’s assumptions.
- Potential dilution and ownership impact from the November placement and future capital raises.